These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49 related articles for article (PubMed ID: 1559663)
1. [A study of the absorption of NPH insulin administered into subcutaneous tissue: in vitro study of the mechanism of insulin release from NPH insulin crystal]. Yanagisawa K Hokkaido Igaku Zasshi; 1992 Jan; 67(1):81-8. PubMed ID: 1559663 [TBL] [Abstract][Full Text] [Related]
2. Structural characterization of insulin NPH formulations. Norrman M; Hubálek F; Schluckebier G Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105 [TBL] [Abstract][Full Text] [Related]
3. ["In vitro" protaminase activity of human plasma and serum and the human carboxypeptidase N (author's transl)]. Blass J; Verriest C; Vicaigne MB; Weiss M Pathol Biol (Paris); 1980 Oct; 28(8):527-34. PubMed ID: 6448971 [TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. Blanco C; Castillo R; Quiralte J; Delgado J; García I; de Pablos P; Carrillo T Allergy; 1996 Jun; 51(6):421-4. PubMed ID: 8837667 [TBL] [Abstract][Full Text] [Related]
5. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro. Duchateau J; Schreyen H; Dorchy H Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314 [TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Levy JH; Zaidan JR; Faraj B Anesth Analg; 1986 Jul; 65(7):739-42. PubMed ID: 2424341 [TBL] [Abstract][Full Text] [Related]
7. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus. Nicolau GY; Haus E; Lakatua DJ; Bogdan C; Petrescu E; Sackett-Lundeen L; Stelea S; Stelea P Endocrinologie; 1984; 22(1):3-16. PubMed ID: 6369501 [TBL] [Abstract][Full Text] [Related]
9. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Luzio SD; Beck P; Owens DR Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275 [TBL] [Abstract][Full Text] [Related]
11. NPH human insulin: does it work in a once-a-day regimen? Gadia M; Sosenko JM; Salzman R; Lauritano AA; Haycock P Clin Ther; 1989; 11(1):120-8. PubMed ID: 2720723 [TBL] [Abstract][Full Text] [Related]
12. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects. Burke B; Andrews WJ; Hadden DR Diabetes Res; 1987 Apr; 4(4):163-7. PubMed ID: 3304782 [TBL] [Abstract][Full Text] [Related]
14. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604 [TBL] [Abstract][Full Text] [Related]
15. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321 [TBL] [Abstract][Full Text] [Related]
16. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Päivärinta M; Tapanainen P; Veijola R Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431 [TBL] [Abstract][Full Text] [Related]
17. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076 [TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307 [TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. DeFelippis MR; Bakaysa DL; Bell MA; Heady MA; Li S; Pye S; Youngman KM; Radziuk J; Frank BH J Pharm Sci; 1998 Feb; 87(2):170-6. PubMed ID: 9519149 [TBL] [Abstract][Full Text] [Related]
20. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]